The PARP inhibitor (PARPi), Olaparib, is currently being evaluated not only for its clinical efficacy in antitumor activity in ovarian and breast cancer but also in mCRPC and SCLC. This evidence concerns the gene PARP1 and small cell lung carcinoma.